上海銳輝醫(yī)藥科技有限公司同時供應以下抑制劑及中間體產(chǎn)品：
電話：15618786686;Email:apishchina@163.com; QQ：2295947952
1 AT-406 1071992-99-8, 1071992-57-8 (HCl)
2 R547 741713-40-6
3 AST 1306 897383-62-9(tosilate)
4 Abiraterone Acetate (CB7630) 154229-18-2
5 Abiraterone(CB-7598) 154229-19-3
6 R788 1025687-58-4
7 R406 841290-80-0
8 AZD6244 606143-52-6, 942275-12-9 (4-methylbenzenesulfonate)
9 Crizotinib (PF-02341066) 877399-52-5
10 SB415286 264218-23-7
11 Bortizomib 179324-69-7
12 Neratinib (HKI-272) 698387-09-6
13 Foretinib (GSK1363089, XL880) 849217-64-7
14 ABT-737 852808-04-9
15 PLX-4032,Vemurafenib 1029872-54-5
16 GDC-0449 879085-55-9
17 GSK-1120212 871700-17-3
18 MDV3100 915087-33-1
19 AMG073 364782-34-3
20 AZD7762 860352-01-8
21 gdc0941 957054-33-0
22 TAK-875 1000413-72-8
23 Ostarine(MK2866) 401900-40-1
24 OSI906 867160-71-2
25 GDC-0980 1032754-93-0
26 LY450139 425386-60-3
27 CAL101 870281-82-6
28 AZD2281 763113-22-0
29 ABT-888 912445-05-7
30 NSC 713200 218600-53-4
31 LY2157299 700874-72-2
32 LY2811376 1194044-20-6
33 LY2886721 1262036-50-9
34 A674563 552325-73-2
35 TAK438 1260141-27-2
36 Everolimus 159351-69-6
37 Telaprevir (VX-950) 402957-28-2
38 MK2048 869901-69-9
39 AG1024 65678-07-1
40 SB705498 501951-42-4
41 pf-5274857 73615-35-0
42 DAPT 208255-80-5
43 GSK1838705A 116235-97-2
44 LY-315920 172732-68-2, 172733-42-5 (sodium salt)
45 PHA767491 845714-00-3
46 SRT1720 1001645-58-4
47 GSK2126458 1086062-66-9
48 GDC-0980 (RG7422) 1032754-93-0
49 ARN509 956104-40-8
50 PF04691502 1013101-36-4
51 LY-364947 6129-53-6
52 BMS-790052 1214735-16-6
53 PR-171 (Carfilzomib) 868540-17-4
54 CP945598HCL 686347-12-6
55 AG-L-59687 793035-88-8
56 A-803467 944261-79-4
57 Ciproxifan 184025-19-2
58 AT7519 HCl 902135-91-5
59 BIX-02188 1094614-85-3
60 CI994 112522-64-2
61 ZM323881HCl 324077-30-7
62 ZM306416 690206-97-4
63 OC000459 851723-84-7
64 BIX-02188 1094614-84-2
65 A-803467 944261-79-4
66 OSI-906 867160-71-2
67 AKR 501 570406-98-3
68 Cedirannib/AZD2171 288383-20-0, 857036-77-2 (Maleic acid)
69 PF-03814735 cas:942487-16-3
70 nelfinavir cas:159989-64-7
71 NVP-BKM120 944396-07-0
72 Olaparib/AZD2281 763113-22-0
73 Bortezomib (Velcade) 179324-69-7
74 Canagliflozin 842133-18-0
75 OSU-03012 742112-33-0
76 CX-4945 1009820-21-6
77 AT-7867 857531-00-1
78 AZD5438 602306-29-6
79 RAF265 927880-90-8
80 MS-275 209783-80-2
81 AS-605240 648450-29-7
82 MG0103/Mocetinostat 26169-73-9
83 LY 2109761 700874-71-1
84 PELITINIB，EKB-569 257933-82-7
85 KU-55933 587871-26-9
86 LY-294002 154447-36-6
87 SGX-523 1022150-57-7
88 XL-147 956958-53-5
89 TIVOZANIB 475108-18-0
90 Cabozantinib 849217-68-1
91 PIK90 677338-12-4
92 AZD-8055 1009298-09-2
93 R-roscovitine 186692-46-6
94 PF-562271 717907-75-0
95 SNS032，BMS-387032 345627-80-7
96 Dabrafenib 1195765-45-7
97 NVP-BGJ398 872511-34-7
98 Panobinostat 404950-80-7
99 NVP-BEZ235 915019-65-7
100 AP-23464 845895-51-4
101 DCC-2618 DCC-2618
102 A-966492 934162-61-5
103 Navitoclax (ABT-263) 923564-51-6
104 ABT-888 912444-00-9
105 Regorafenib (BAY 73-4506) 755037-03-7
106 Roflumilast，Daxas 162401-32-3
107 Fasudil hydrochloride 105628-07-7
108 Pelitinib (EKB-569) 257933-82-7
109 Dacomitinib(PF299804) 1110813-31-4
110 Imatinib (Gleevec) 152459-95-5
111 Erlotinib HCl 183319-69-9
112 Afatinib(BIBW2992) 439081-18-2
113 PCI-32765 Ibrutinib 936563-96-1
114 XL518 ,GDC-0973 934660-93-2
115 AP24534（ponatinib） 943319-70-8
116 AT-101 90141-22-3
117 WZ4002 1213269-23-8
118 Cediranib (AZD2171) 288383-20-0
119 Vandetanib (Zactima) 443913-73-3
120 A-674563 552325-73-2
121 Rucaparib (AG-014699, PF-01367338) 59868-92-9
122 BMS-599626 (AC480) 714971-09-2, 873837-23-1 (HCl), 873837-22-0 (H2O)
123 GDC 0879 5281-76-7
124 Tivozanib (AV-951) 475108-18-0
125 R-roscovitine 186692-46-6
126 Regorafenib (BAY 73-4506) 755037-03-7
127 PAC-1 315183-21-2
128 Crizotinib （PF-02341066） 877399-52-5
129 Bortezomib 179324-69-7
130 AMG208 1002304-34-8
131 PF02341066 77399-52-5
132 CP-91149 186392-40-5
133 Dinaciclib (SCH727965) 779353-01-4
134 AZD6482 1173900-33-8
135 CHIR-99021 (CT99021) 252917-06-9
136 GSK690693 937174-76-0
137 tariquidar(xl-9576) 206873-63-4
138 XL-184 free base (Cabozantinib) 849217-68-1
139 XL765(SAR245409) 1123889-87-1
140 ABT-102 808756-71-0
141 AZD8055 1009298-09-2, 1201799-04-3 (D(-)-Tartaric Acid), 1201799-05-4 (Fumaric acid)
142 Neratinib (HKI-272) 698387-09-6
143 PF-05212384 (PKI-587) 1197160-78-3
144 PHA665752 477575-56-7
145 SGI1776 1025065-69-3
146 YO01027 209984-56-5
147 AZD2014 1009298-59-2
148 EMD-1214063 1100598-32-0
149 XI-006 (NSC207895) 58131-57-0
150 SCH727965 779353-01-4
151 Dapagliflozin 461432-26-8
152 PHA-665752 477575-56-7
153 SU11274 658084-23-2
154 VN124-1 (TOK-001) 851983-85-2
155 PCI-32765 (Ibrutinib) 936563-96-1
156 GDC 0879 905281-76-7
157 WZ4002 1213269-23-8
158 ABT-869 796967-16-3
159 SRT3109 1204707-71-0
160 VX-680 639089-54-6
161 CYT387 1056634-68-4
162 PF-04971729 1210344-57-2
163 AZD2281 763113-22-0
164 KX2-391 897016-82-9
165 ADX47273 851881-60-2)
166 Losartan potassium 124750-99-8
167 Dapagliflozin 461432-26-8
168 PF573228 869288-64-2
169 Delanzomib (CEP-18770) 847499-27-8
170 TAK-285 871026-44-7
171 OSI-930 728033-96-3
172 4SC-201 864814-88-0
173 Ponatinib (AP24534) 943319-70-8, 1232836-25-7(3HCl)
174 AV412 451492-95-8
175 PF-429242 947303-87-9
176 BAY 73-4506 755037-03-7
177 AT7519 844442-38-2, 902135-91-5 (HCl), 902135-89-1(methanesulfonate)
178 VX-680 639089-54-6
179 SB-203580 152121-47-6
180 CAL-101 870281-82-6
181 AZD4547 1035270-39-3
182 CEP-18770 847499-27-8
183 PF-573228 869288-64-2
184 TAK-285 871026-44-7
185 MK0752 471905-41-6
186 Pralatrexate 146464-95-1
187 LY315920 172732-68-2
188 MDV3100 915087-33-1
189 Indisulam 165668-41-7
190 GSK2636771 1372540-25-4
191 BYl-719 1217486-61-7
192 LY2886721 1262036-50-9
193 AP24534 943319-70-8
194 PF-04217903 956905-27-4
195 PLX-4032 918505-61-0
196 A769662 844499-71-4
197 TG101209 936091-14-4
198 AZD7762 860352-01-8
199 WP1066 7064-38-1
200 PD 173074 219580-11-7
201 ML-7 HYDROCHLORIDE 109376-83-2
202 BIBR 953(Dabigatran, Pradaxa), 211914-51-1
203 Sirtinol 410536-97-9
204 A-803467 944261-79-4
205 PLX 4720 918505-84-7
********************************************************
1, Intermediate,, CAS:, 214360-73-3
2, Intermediate,, CAS:, 210907-84-9
3, Intermediate,, CAS:, 191171-55-8
4, Intermediate,, CAS:, 847664-64-6
5, Intermediate,, CAS:, 850567-49-6
6, Intermediate,, CAS:, 1007882-12-3
7, Intermediate,, CAS:, 112671-42-8
8, Intermediate,, CAS:, 21535-97-7
9, Intermediate,, CAS:, 934-37-2
10, Intermediate,, CAS:, 51285-26-8
11, Intermediate,, CAS:, 82019-89-4
12, Intermediate,, CAS:, 53400-41-2
13, Intermediate,, CAS:, 65902-59-2
14, Intermediate,, CAS:, 7254-34-4
15, Intermediate,, CAS:, 13750-81-7
關鍵字：
上海銳輝醫(yī)藥科技有限公司位于上海張江生物醫(yī)藥基地，公司主要從事醫(yī)藥及中間體的定制合成，具有自主創(chuàng)新性的新藥研究開發(fā)工作，同時也為醫(yī)藥生產(chǎn)企業(yè)提供生產(chǎn)技術改進、新藥委托開發(fā)服務。公司致力于醫(yī)藥原料藥和醫(yī)藥中間體的研究開發(fā)，同時也側重于工藝優(yōu)化。公司現(xiàn)擁有合成實驗室200余平米，擁有現(xiàn)代化的辦公條件和環(huán)境。配有各種研發(fā)用實驗設備，可同時承擔多個新藥品種的研發(fā)；公司同時裝備公斤級別中試實驗室，為優(yōu)勢產(chǎn)品的工藝放大和生產(chǎn)奠定了基礎。公司與國內外各醫(yī)藥研究機構，張江公共服務平臺建立了良好的合作關系，方便使用其核磁、質譜、LC-MS 等精密儀器的檢測。公司現(xiàn)有的儀器設備等硬件條件完全有能力滿足項目產(chǎn)業(yè)化的生產(chǎn)需求